SLC5A2 and heart failure: For example, the DAPA-HF and DELIVER trials, which evaluated the efficacy of dapagliflozin (a sodium glucose transporter 2 [SGLT2] inhibitor) in patients with heart failure, reported a combined WR of 1.10 (95% confidence interval: 1.06-1.15) with a P value < 0.001.26